Cargando…
Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2 (+) mononuclear phagocyte differentiation in liver cancer
Preclinical studies have proven that nanosecond pulsed electric field (nsPEF) ablation can be a safe and effective treatment for humans with unresectable liver cancer that are ineligible for thermal ablation. The concomitant activation of antitumor immunity by nsPEF can also potentially prevent tumo...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257421/ https://www.ncbi.nlm.nih.gov/pubmed/36587393 http://dx.doi.org/10.1002/1878-0261.13372 |
_version_ | 1785057298275631104 |
---|---|
author | Liu, Jingqi Fang, Chengyu Jin, Xinyan Tian, Guo Sun, Zhongxia Hong, Lijie Pan, Jinhua Chen, Xinhua Zhao, Jun Cao, Hongcui Jiang, Tianan |
author_facet | Liu, Jingqi Fang, Chengyu Jin, Xinyan Tian, Guo Sun, Zhongxia Hong, Lijie Pan, Jinhua Chen, Xinhua Zhao, Jun Cao, Hongcui Jiang, Tianan |
author_sort | Liu, Jingqi |
collection | PubMed |
description | Preclinical studies have proven that nanosecond pulsed electric field (nsPEF) ablation can be a safe and effective treatment for humans with unresectable liver cancer that are ineligible for thermal ablation. The concomitant activation of antitumor immunity by nsPEF can also potentially prevent tumor recurrence. However, whether nsPEF exhibits similar efficacy in a clinical setting remains to be investigated. A prospective clinical trial (clinicaltrials.gov identifier: NCT04039747) was conducted to evaluate the safety and efficacy of ultrasound (US)‐guided nsPEF ablation in 15 patients with unresectable liver cancer that were ineligible for thermal ablation. We found that nsPEF ablation was safe and produced a 12‐month recurrence‐free survival (RFS) and local RFS of 60% (9/15) and 86.7% (13/15), respectively, in the enrolled patients. Integrative proteomic and metabolomic analysis showed that sphingolipid metabolism was the most significantly enriched pathway in patient sera after nsPEF without recurrence within 8 months. A similar upregulation of sphingolipid metabolism was observed in the intratumoral mononuclear phagocytes (MNPs), rather than other immune and nonimmune cells, of an nsPEF‐treated mouse model. We then demonstrated that lymphocyte antigen 6 complex, locus C2‐positive (Ly6c2 (+)) monocytes first differentiated into Ly6c2 (+) monocyte‐derived macrophages with an increase in sphingolipid metabolic activity, and subsequently into Ly6c2 (+) dendritic cells (DCs). Ly6c2 (+) DCs communicated with CD8(+) T cells and increased the proportions of IFN‐γ(+) CD8(+) memory T cells after nsPEF, and this finding was subsequently confirmed by depletion of liver Ly6c2 (+) MNPs. In conclusion, nsPEF was a safe and effective treatment for liver cancer. The alteration of sphingolipid metabolism induced by nsPEF was associated with the differentiation of Ly6c2 (+) MNPs, and subsequently induced the formation of memory CD8(+) T cells with potent antitumor effect. |
format | Online Article Text |
id | pubmed-10257421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102574212023-06-11 Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2 (+) mononuclear phagocyte differentiation in liver cancer Liu, Jingqi Fang, Chengyu Jin, Xinyan Tian, Guo Sun, Zhongxia Hong, Lijie Pan, Jinhua Chen, Xinhua Zhao, Jun Cao, Hongcui Jiang, Tianan Mol Oncol Research Articles Preclinical studies have proven that nanosecond pulsed electric field (nsPEF) ablation can be a safe and effective treatment for humans with unresectable liver cancer that are ineligible for thermal ablation. The concomitant activation of antitumor immunity by nsPEF can also potentially prevent tumor recurrence. However, whether nsPEF exhibits similar efficacy in a clinical setting remains to be investigated. A prospective clinical trial (clinicaltrials.gov identifier: NCT04039747) was conducted to evaluate the safety and efficacy of ultrasound (US)‐guided nsPEF ablation in 15 patients with unresectable liver cancer that were ineligible for thermal ablation. We found that nsPEF ablation was safe and produced a 12‐month recurrence‐free survival (RFS) and local RFS of 60% (9/15) and 86.7% (13/15), respectively, in the enrolled patients. Integrative proteomic and metabolomic analysis showed that sphingolipid metabolism was the most significantly enriched pathway in patient sera after nsPEF without recurrence within 8 months. A similar upregulation of sphingolipid metabolism was observed in the intratumoral mononuclear phagocytes (MNPs), rather than other immune and nonimmune cells, of an nsPEF‐treated mouse model. We then demonstrated that lymphocyte antigen 6 complex, locus C2‐positive (Ly6c2 (+)) monocytes first differentiated into Ly6c2 (+) monocyte‐derived macrophages with an increase in sphingolipid metabolic activity, and subsequently into Ly6c2 (+) dendritic cells (DCs). Ly6c2 (+) DCs communicated with CD8(+) T cells and increased the proportions of IFN‐γ(+) CD8(+) memory T cells after nsPEF, and this finding was subsequently confirmed by depletion of liver Ly6c2 (+) MNPs. In conclusion, nsPEF was a safe and effective treatment for liver cancer. The alteration of sphingolipid metabolism induced by nsPEF was associated with the differentiation of Ly6c2 (+) MNPs, and subsequently induced the formation of memory CD8(+) T cells with potent antitumor effect. John Wiley and Sons Inc. 2023-01-21 /pmc/articles/PMC10257421/ /pubmed/36587393 http://dx.doi.org/10.1002/1878-0261.13372 Text en © 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Liu, Jingqi Fang, Chengyu Jin, Xinyan Tian, Guo Sun, Zhongxia Hong, Lijie Pan, Jinhua Chen, Xinhua Zhao, Jun Cao, Hongcui Jiang, Tianan Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2 (+) mononuclear phagocyte differentiation in liver cancer |
title | Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2
(+) mononuclear phagocyte differentiation in liver cancer |
title_full | Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2
(+) mononuclear phagocyte differentiation in liver cancer |
title_fullStr | Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2
(+) mononuclear phagocyte differentiation in liver cancer |
title_full_unstemmed | Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2
(+) mononuclear phagocyte differentiation in liver cancer |
title_short | Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2
(+) mononuclear phagocyte differentiation in liver cancer |
title_sort | nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with ly6c2
(+) mononuclear phagocyte differentiation in liver cancer |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257421/ https://www.ncbi.nlm.nih.gov/pubmed/36587393 http://dx.doi.org/10.1002/1878-0261.13372 |
work_keys_str_mv | AT liujingqi nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer AT fangchengyu nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer AT jinxinyan nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer AT tianguo nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer AT sunzhongxia nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer AT honglijie nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer AT panjinhua nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer AT chenxinhua nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer AT zhaojun nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer AT caohongcui nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer AT jiangtianan nanosecondpulsedelectricfieldablationinducedmodulationofsphingolipidmetabolismisassociatedwithly6c2mononuclearphagocytedifferentiationinlivercancer |